Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Express Scripts

Last Updated: January 24, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for Tamibarotene

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

What is the drug development status for Tamibarotene?

Tamibarotene is an investigational drug.

There have been 8 clinical trials for Tamibarotene. The most recent clinical trial was a Phase 2 trial, which was initiated on January 1st 2011.

The most common disease conditions in clinical trials are Leukemia, Leukemia, Promyelocytic, Acute, and Paraparesis. The leading clinical trial sponsors are CytRx, Osaka City University, and Northwestern University.

There are three hundred and forty-three US patents protecting this investigational drug and two international patents.

Recent Clinical Trials for Tamibarotene
A Biomarker-Directed Phase 2 Trial of SY-1425 in Patients With Acute Myeloid Leukemia or Myelodysplastic SyndromeSyros PharmaceuticalsPhase 2
First Line Study of Tamibarotene in Combination for Advanced Non-Small Cell Lung CancerCytRxPhase 2
Efficacy and Safety of Tamibarotene(AM80H) for HTLV-1 Associated Myelopathy/ Tropical Spastic Paraparesis (HAM/TSP)St. Marianna University School of MedicinePhase 2/Phase 3

See all Tamibarotene clinical trials

Clinical Trial Summary for Tamibarotene

Top disease conditions for Tamibarotene
Top clinical trial sponsors for Tamibarotene

See all Tamibarotene clinical trials

US Patents for Tamibarotene

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
Tamibarotene   Start Trial Anticancer agent Kyoto Pharmaceutical Industries, Ltd. (Kyoto, JP) Sumitomo Dainippon Pharma Co., Ltd. (Osaka, JP)   Start Trial
Tamibarotene   Start Trial Pyrrolidinone derivatives as MetAP-2 inhibitors Merck Patent GmbH (Darmstadt, DE)   Start Trial
Tamibarotene   Start Trial .beta.-substituted .beta.-amino acids and analogs as chemotherapeutic agents and uses thereof Quadriga Biosciences, Inc. (Los Altos, CA)   Start Trial
Tamibarotene   Start Trial Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) BAYER PHARMA AKTIENGESELLSCHAFT (Berlin, DE)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for Tamibarotene

Drugname Country Document Number Estimated Expiration Related US Patent
Tamibarotene Australia 2015272560 2034-06-09   Start Trial
Tamibarotene Canada 2951627 2034-06-09   Start Trial
Tamibarotene European Patent Office 3153508 2034-06-09   Start Trial
Tamibarotene Japan 6549115 2034-06-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.